Autologous hematopoietic stem cell transplantation in non-hodgkin lymphomas

Natthapol Songdej, Eric S. Winer

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Non-HodgkinLymphomais aheterogeneous group oflymphoidmalignancies that involves mature B-cells, mature T-cells, and their progenitors. Although novel chemotherapy and immunotherapy regimens have improved rates of complete response and overall survival, autologous stem cell transplant (ASCT) is used in both the front-line and relapsed setting to further improve these markers and potentially cure. Even in indolent lymphomas, ASCT shows a definite improvement in progression-free survival, although no improvement in overall survival. The most promising results for front-line ASCT are in mantle cell lymphoma (MCL), where there is evidence of long-term progression-free and overall survival with evidence of a cured fraction. In the relapsed setting, ASCT is the standard of care in diffuse large B-cell lymphoma, though results of ASCT in the relapsed setting for MCL and Burkitt lymphoma are disappointing. The role and timing of ASCT in peripheral T-cell lymphomas are yet to be defined, but front-line ASCT in enteropathy-associated T-cell lymphoma and advanced-stage cutaneous T-cell lymphoma shows promise for improving long-term outcomes. Additional studies on front-line and relapsed ASCT with novel chemotherapy and immunotherapy regimens may demonstrate further improved responses and survival, especially for high-risk patients.

Original languageEnglish (US)
Title of host publicationNon-Hodgkin Lymphoma
Subtitle of host publicationPrognostic Factors and Targets
PublisherSpringer New York
Pages247-266
Number of pages20
ISBN (Electronic)9781461458517
ISBN (Print)9781461458500
DOIs
StatePublished - Jan 1 2013

Fingerprint

Hematopoietic Stem Cell Transplantation
Non-Hodgkin's Lymphoma
Stem Cells
Transplants
Mantle-Cell Lymphoma
Immunotherapy
Disease-Free Survival
Survival
Enteropathy-Associated T-Cell Lymphoma
Peripheral T-Cell Lymphoma
Drug Therapy
Cutaneous T-Cell Lymphoma
Burkitt Lymphoma
Lymphoma, Large B-Cell, Diffuse
Standard of Care
Lymphoma
B-Lymphocytes
T-Lymphocytes

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Songdej, N., & Winer, E. S. (2013). Autologous hematopoietic stem cell transplantation in non-hodgkin lymphomas. In Non-Hodgkin Lymphoma: Prognostic Factors and Targets (pp. 247-266). Springer New York. https://doi.org/10.1007/978-1-4614-5851-7_14
Songdej, Natthapol ; Winer, Eric S. / Autologous hematopoietic stem cell transplantation in non-hodgkin lymphomas. Non-Hodgkin Lymphoma: Prognostic Factors and Targets. Springer New York, 2013. pp. 247-266
@inbook{8ba7158d9aaa4541bdc52e3663f4c1b3,
title = "Autologous hematopoietic stem cell transplantation in non-hodgkin lymphomas",
abstract = "Non-HodgkinLymphomais aheterogeneous group oflymphoidmalignancies that involves mature B-cells, mature T-cells, and their progenitors. Although novel chemotherapy and immunotherapy regimens have improved rates of complete response and overall survival, autologous stem cell transplant (ASCT) is used in both the front-line and relapsed setting to further improve these markers and potentially cure. Even in indolent lymphomas, ASCT shows a definite improvement in progression-free survival, although no improvement in overall survival. The most promising results for front-line ASCT are in mantle cell lymphoma (MCL), where there is evidence of long-term progression-free and overall survival with evidence of a cured fraction. In the relapsed setting, ASCT is the standard of care in diffuse large B-cell lymphoma, though results of ASCT in the relapsed setting for MCL and Burkitt lymphoma are disappointing. The role and timing of ASCT in peripheral T-cell lymphomas are yet to be defined, but front-line ASCT in enteropathy-associated T-cell lymphoma and advanced-stage cutaneous T-cell lymphoma shows promise for improving long-term outcomes. Additional studies on front-line and relapsed ASCT with novel chemotherapy and immunotherapy regimens may demonstrate further improved responses and survival, especially for high-risk patients.",
author = "Natthapol Songdej and Winer, {Eric S.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1007/978-1-4614-5851-7_14",
language = "English (US)",
isbn = "9781461458500",
pages = "247--266",
booktitle = "Non-Hodgkin Lymphoma",
publisher = "Springer New York",
address = "United States",

}

Songdej, N & Winer, ES 2013, Autologous hematopoietic stem cell transplantation in non-hodgkin lymphomas. in Non-Hodgkin Lymphoma: Prognostic Factors and Targets. Springer New York, pp. 247-266. https://doi.org/10.1007/978-1-4614-5851-7_14

Autologous hematopoietic stem cell transplantation in non-hodgkin lymphomas. / Songdej, Natthapol; Winer, Eric S.

Non-Hodgkin Lymphoma: Prognostic Factors and Targets. Springer New York, 2013. p. 247-266.

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Autologous hematopoietic stem cell transplantation in non-hodgkin lymphomas

AU - Songdej, Natthapol

AU - Winer, Eric S.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Non-HodgkinLymphomais aheterogeneous group oflymphoidmalignancies that involves mature B-cells, mature T-cells, and their progenitors. Although novel chemotherapy and immunotherapy regimens have improved rates of complete response and overall survival, autologous stem cell transplant (ASCT) is used in both the front-line and relapsed setting to further improve these markers and potentially cure. Even in indolent lymphomas, ASCT shows a definite improvement in progression-free survival, although no improvement in overall survival. The most promising results for front-line ASCT are in mantle cell lymphoma (MCL), where there is evidence of long-term progression-free and overall survival with evidence of a cured fraction. In the relapsed setting, ASCT is the standard of care in diffuse large B-cell lymphoma, though results of ASCT in the relapsed setting for MCL and Burkitt lymphoma are disappointing. The role and timing of ASCT in peripheral T-cell lymphomas are yet to be defined, but front-line ASCT in enteropathy-associated T-cell lymphoma and advanced-stage cutaneous T-cell lymphoma shows promise for improving long-term outcomes. Additional studies on front-line and relapsed ASCT with novel chemotherapy and immunotherapy regimens may demonstrate further improved responses and survival, especially for high-risk patients.

AB - Non-HodgkinLymphomais aheterogeneous group oflymphoidmalignancies that involves mature B-cells, mature T-cells, and their progenitors. Although novel chemotherapy and immunotherapy regimens have improved rates of complete response and overall survival, autologous stem cell transplant (ASCT) is used in both the front-line and relapsed setting to further improve these markers and potentially cure. Even in indolent lymphomas, ASCT shows a definite improvement in progression-free survival, although no improvement in overall survival. The most promising results for front-line ASCT are in mantle cell lymphoma (MCL), where there is evidence of long-term progression-free and overall survival with evidence of a cured fraction. In the relapsed setting, ASCT is the standard of care in diffuse large B-cell lymphoma, though results of ASCT in the relapsed setting for MCL and Burkitt lymphoma are disappointing. The role and timing of ASCT in peripheral T-cell lymphomas are yet to be defined, but front-line ASCT in enteropathy-associated T-cell lymphoma and advanced-stage cutaneous T-cell lymphoma shows promise for improving long-term outcomes. Additional studies on front-line and relapsed ASCT with novel chemotherapy and immunotherapy regimens may demonstrate further improved responses and survival, especially for high-risk patients.

UR - http://www.scopus.com/inward/record.url?scp=85028509797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028509797&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-5851-7_14

DO - 10.1007/978-1-4614-5851-7_14

M3 - Chapter

AN - SCOPUS:85028509797

SN - 9781461458500

SP - 247

EP - 266

BT - Non-Hodgkin Lymphoma

PB - Springer New York

ER -

Songdej N, Winer ES. Autologous hematopoietic stem cell transplantation in non-hodgkin lymphomas. In Non-Hodgkin Lymphoma: Prognostic Factors and Targets. Springer New York. 2013. p. 247-266 https://doi.org/10.1007/978-1-4614-5851-7_14